Previous animal and clinical studies have also revealed that statins decrease cancer incidence and improve cancer-related mortality [15,16,17]; however, lower therapeutic efficacy and the resistance of statins in the treatment of cardiovascular diseases and cancer via SREBP2-mediated compensation of cholesterol biosynthesis are two of the issues faced since the clinical application of statins [18,19,20]. The gene discussed is SREBF2; the disease is cancer.